胃癌腹腔灌洗细胞学阳性或局限性腹膜转移的治疗结局
这项回顾性多中心队列研究纳入1181例CY1和/或P1a胃癌患者,比较先手术与先化疗策略。转化至P0CY0后手术者5年OS达50.5%。
要点
- 先化疗后手术的5年OS优于先手术加术后化疗(39.9% vs 31.4%)
- 转化至P0CY0后手术预后最佳,5年OS为50.5%
- 未转化至P0CY0即手术者5年OS仅17.2%
核心结论
- 对于CY1和/或P1a胃癌,先化疗后手术的5年OS略高于先手术加术后化疗。
- 转化至P0CY0后手术与最有利的生存相关,值得开发更有效的术前化疗。
研究设计与样本
- 回顾性多中心队列研究,日本临床肿瘤组胃癌研究组48家机构参与。
- 纳入2016至2022年治疗的CY1和/或P1a且无其他远处转移的胃癌患者1181例。
- 按初始治疗分层:先手术838例(71%),先化疗343例(29%)。
- 先化疗组再分为单纯化疗205例、转化至P0CY0后手术92例、未转化手术46例。
主要发现
- 中位年龄72岁(IQR 65-78),男性725例(61%),女性456例(39%)。
- 总体5年OS率为25.0%(95%CI 22.3%-28.0%),中位生存时间24.3个月。
- 单纯手术和单纯化疗预后差,5年OS分别为10.3%和3.2%;转化至P0CY0后手术5年OS为50.5%,未转化者为17.2%。
临床怎么用
- 对CY1和/或P1a胃癌,可考虑先化疗后手术策略,尤其争取转化至P0CY0后再行胃切除。
- 未转化至P0CY0者手术预后有限,需权衡手术获益。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 先化疗组内细分依据术前化疗疗效,非随机分组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the era of modern systemic chemotherapy, the optimal treatment strategy for gastric cancer with positive peritoneal lavage cytology (CY1) and/or localized peritoneal metastasis (P1a) remains controversial. OBJECTIVE: To explore the optimal treatment strategy for patients with gastric cancer with CY1 and/or P1a by comparing the outcomes of various therapeutic strategies. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a retrospective multicenter study set in 48 institutions of the Stomach Cancer Study Group in the Japan Clinical Oncology Group. Participants were patients with gastric cancer with CY1 and/or P1a, but no other distant metastases, who were treated in 2016 to 2022. Data were analyzed from July 2025 to May 2026. EXPOSURE: Patients were stratified according to initial treatment: upfront gastrectomy (n = 838 [71%]) or upfront chemotherapy (n = 343 [29%]). The upfront chemotherapy group was further subdivided into chemotherapy alone (n = 205), gastrectomy after conversion to P0CY0 (n = 92), and nonconversion gastrectomy (n = 46) according to preoperative chemotherapy efficacy. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (OS), and secondary outcomes included progression-free survival. RESULTS: Among 1181 patients, the median (IQR) age was 72 (65-78) years; 725 patients (61%) were male and 456 (39%) were female. The overall 5-year OS rate was 25.0% (95% CI, 22.3%-28.0%), with a median survival time of 24.3 months. Upfront gastrectomy showed a significantly longer OS than upfront chemotherapy (5-year OS: 27.6% vs 19.0%; hazard ratio, 0.80; 95% CI, 0.69-0.93; P = .004). Among the multimodal treatment strategies, upfront chemotherapy followed by gastrectomy showed a significantly higher 5-year OS rate than upfront gastrectomy with postoperative chemotherapy (39.9%; 95% CI, 31.7%-50.2%, vs 31.4%; 95% CI, 27.6%-35.8%; P = .01). Gastrectomy alone and chemotherapy alone showed poor prognoses (10.3% and 3.2%, respectively). Notably, survival after gastrectomy following conversion to P0CY0 was the most favorable (5-year OS: 50.5%), whereas that without P0CY0 was modest (5-year OS: 17.2%). CONCLUSIONS AND RELEVANCE: This study found that for gastric cancer with CY1 and/or P1a, upfront chemotherapy followed by gastrectomy resulted in a slightly higher 5-year OS rate than upfront gastrectomy followed by postoperative chemotherapy. Because gastrectomy after conversion to P0CY0 was associated with the most favorable survival, the development of more effective preoperative chemotherapy is warranted.
引用
- Fujiya K, Tokunaga M, Yamamoto K, et al. Treatment Outcomes for Gastric Cancer With Positive Peritoneal Lavage Cytology or Localized Peritoneal Metastasis. JAMA Surg. 2026. PMID: 42842264. doi:10.1001/jamasurg.2026.4647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。